Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KEAP1 | Q14145 | 1/20 | 0.53 |
| ▸ | PRMT6 | Q96LA8 | 1/20 | 0.50 |
| ▸ | PIK3R1 | P27986 | 1/20 | 0.47 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.46 |
| ▸ | RAB9A | P51151 | 3/20 | 0.46 |
| ▸ | NOTUM | Q6P988 | 1/20 | 0.46 |
| ▸ | TAAR1 | Q96RJ0 | 2/20 | 0.46 |
| ▸ | SOS1 | Q07889 | 1/20 | 0.45 |
| ▸ | GABRP | O00591 | 2/20 | 0.44 |
| ▸ | GABRD | O14764 | 2/20 | 0.44 |
| ▸ | GABRA1 | P14867 | 2/20 | 0.44 |
| ▸ | GABRB1 | P18505 | 2/20 | 0.44 |
| ▸ | GABRG2 | P18507 | 2/20 | 0.44 |
| ▸ | GABRB3 | P28472 | 2/20 | 0.44 |
| ▸ | GABRA5 | P31644 | 2/20 | 0.44 |
| ▸ | GABRA3 | P34903 | 2/20 | 0.44 |
| ▸ | GABRA2 | P47869 | 2/20 | 0.44 |
| ▸ | GABRB2 | P47870 | 2/20 | 0.44 |
| ▸ | GABRA4 | P48169 | 2/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29498760 | 1.00 | KEAP1 (0.53) | KEAP1PRMT6PIK3R1PIK3CAALDH1A1 | |
| SCHEMBL244155 | 0.79 | — | — | |
| SCHEMBL28323221 | 0.77 | TAAR1 (0.62) | KEAP1PRMT6ALDH1A1RAB9ATAAR1 | |
| SCHEMBL27761661 | 0.77 | KEAP1 (0.59) | KEAP1PRMT6PIK3R1PIK3CAALDH1A1 | |
| SCHEMBL1478175 | 0.76 | TAAR1 (0.61) | PIK3R1PIK3CAALDH1A1RAB9ANOTUM | |
| SCHEMBL23567449 | 0.75 | PIK3R1 (0.54) | KEAP1PRMT6PIK3R1PIK3CAALDH1A1 | |
| SCHEMBL6765578 | 0.75 | KEAP1 (0.58) | KEAP1PRMT6ALDH1A1RAB9ATAAR1 | |
| SCHEMBL2462178 | 0.75 | TAAR1 (0.61) | KEAP1PRMT6ALDH1A1TAAR1KDM4E | |
| SCHEMBL22423671 | 0.75 | KEAP1 (0.53) | KEAP1PRMT6PIK3R1PIK3CAALDH1A1 | |
| SCHEMBL11064449 | 0.75 | PRMT6 (0.54) | KEAP1PRMT6ALDH1A1RAB9ATAAR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-105209449-B | Inhibitors of the kynurenine pathway | 库拉德夫制药私人有限公司 | 2019-02-01 | — | — | CN | claimed |
| CN-106052158-A | Special tank type heat exchange device for manganese slag light ceramic tile additive, control method and key component manufacturing process of special tank type heat exchange device | 徐州工程学院 | 2016-10-26 | — | — | CN | claimed |
| CN-114425390-B | Preparation method and application of 3D printing catalyst loaded with carbon quantum dots | 南京师范大学 | 2024-07-09 | — | — | CN | disclosed |
| CN-114516880-B | Method for synthesizing furo [2,3-b ] quinoxaline derivative | 桂林理工大学 | 2023-11-17 | — | — | CN | disclosed |
| CN-114616280-B | Heterophasic propylene ethylene copolymer compositions with desirable balance of mechanical properties | 北欧化工公司 | 2023-10-13 | — | — | CN | disclosed |
| CN-114516880-A | Novel method for synthesizing furo [2,3-b ] quinoxaline derivative | 桂林理工大学 | 2022-05-20 | — | — | CN | disclosed |
| CN-114425390-A | Preparation method and application of carbon quantum dot-loaded 3D printing catalyst | 南京师范大学 | 2022-05-03 | — | — | CN | disclosed |
| CN-106052158-A | Special tank type heat exchange device for manganese slag light ceramic tile additive, control method and key component manufacturing process of special tank type heat exchange device | 徐州工程学院 | 2016-10-26 | — | — | CN | disclosed |
| US-7915280-B2 | Compounds and their uses | EISAI INC. (US) | 2011-03-29 | — | — | US | disclosed |
| US-RE41150-E1 | Poly(adenosine 5'-diphospho-ribose) polymerase (PARP) inhibitors; compounds based on thieno(4,3,2-ef)(2)benzazepin-6-one | EISAI CORPORATION OF NORTH AMERICA (US) | 2010-02-23 | — | — | US | disclosed |
| US-7662839-B2 | EP2 receptor agonists | ASTERAND UK LIMITED (GB) | 2010-02-16 | — | — | US | disclosed |
| US-7235557-B2 | Compounds and their uses | MGI GP, INC. (US) | 2007-06-26 | — | — | US | disclosed |
| US-20060142266-A1 | Compounds and their uses | MGI GP, INC. (US) | 2006-06-29 | — | — | US | disclosed |
| US-20060003987-A1 | Compounds and their uses | GUILFORD PHARMACEUTICALS, INC. (US) | 2006-01-05 | — | — | US | disclosed |
| US-20050148575-A1 | (Di)Azepino[5,4,3-cd]benzothiophenes; poly(ADP-ribose) polymerase (PARP) and glycohydrolase (PARG) inhibitor; antiinflammatory; protects cells, tissue and organs against the ill-effects of reactive free radicals and nitric oxide, and damage following focal ischemia and reperfusion injury | GUILFORD PHARMACEUTICALS INC. (US) | 2005-07-07 | — | — | US | disclosed |
| US-6887996-B2 | Poly(adenosine 5'-diphospho-ribose) polymerase (PARP) inhibitors; compounds based on thieno(4,3,2-ef)(2)benzazepin-6-one | GUILFORD PHARMACEUTICALS INC. (US) | 2005-05-03 | — | — | US | disclosed |
| CN-1474816-A | 4-amino-quinazolines | Ĭ��ר���ɷ�����˾ | 2004-02-11 | — | — | CN | disclosed |
| EP-1339402-A2 | BENZOAZEPINE AND BENZODIAZEPINE DERIVATIVES AND THEIR USE AS PARP INHIBITORS | GUILFORD PHARMACEUTICALS INC. (US) | 2003-09-03 | — | — | EP | disclosed |
| US-20030022883-A1 | Compounds and their use | EISAI INC. | 2003-01-30 | — | — | US | disclosed |
| WO-2002044183-A2 | BENZOAZEPINE AND BENZODIAZEPINE DERIVATIVES AND THEIR USE AS PARP INHIBITORS | GUILFORD PHARMACEUTICALS INC. (US) | 2002-06-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030022883-A1 | Compounds and their use | PARP1, PARP2, PARP3 | KEAP1 324/4885PRMT6 959/4885PIK3R1 343/4885 |
| US-20060003987-A1 | Compounds and their uses | PARP1, PARP2, PARP3 | KEAP1 563/4885PRMT6 941/4885PIK3R1 575/4885 |
| US-20050148575-A1 | (Di)Azepino[5,4,3-cd]benzothiophenes; poly(ADP-ribose) polymerase (PARP) and glycohydrolase (PARG) inhibitor; antiinflammatory; protects cells, tissue and organs against the ill-effects of reactive free radicals and nitric oxide, and damage following focal ischemia and reperfusion injury | PARP1, PARP11, PARP15 | KEAP1 558/4885PRMT6 1879/4885PIK3R1 1076/4885 |
| US-20060142266-A1 | Compounds and their uses | PARP1, PARP2, PARP3 | KEAP1 563/4885PRMT6 941/4885PIK3R1 575/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.